TORNTPHARM Overzicht aandelen
Torrent Pharmaceuticals Limited houdt zich bezig met onderzoek, ontwikkeling, productie en marketing van generieke farmaceutische formuleringen in India, de Verenigde Staten, Brazilië en Duitsland. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 0/6 |
| Toekomstige groei | 5/6 |
| Prestaties in het verleden | 6/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 4/6 |
Torrent Pharmaceuticals Limited Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | ₹3,167.10 |
| 52 Week Hoogtepunt | ₹3,590.70 |
| 52 Week Laag | ₹2,025.70 |
| Bèta | 0.26 |
| 11 maand verandering | -7.74% |
| 3 maanden verandering | -5.26% |
| 1 Jaar Verandering | 51.48% |
| 33 jaar verandering | 108.63% |
| 5 jaar verandering | 233.62% |
| Verandering sinds IPO | 26,292.50% |
Recent nieuws en updates
Earnings Miss: Torrent Pharmaceuticals Limited Missed EPS By 7.7% And Analysts Are Revising Their Forecasts
Oct 29
Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) Popularity With Investors Is Under Threat From Overpricing
Oct 24Recent updates
Earnings Miss: Torrent Pharmaceuticals Limited Missed EPS By 7.7% And Analysts Are Revising Their Forecasts
Oct 29Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) Popularity With Investors Is Under Threat From Overpricing
Oct 24Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Just Reported And Analysts Have Been Lifting Their Price Targets
Jul 26Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) P/E Is On The Mark
Apr 16Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?
Mar 03Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Increasing Its Dividend To ₹22.00
Feb 05Investors Interested In Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) Earnings
Jan 07Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Rather Sparingly
Nov 14Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jun 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Mar 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jul 25Torrent Pharmaceuticals' (NSE:TORNTPHARM) Soft Earnings Don't Show The Whole Picture
Jun 02Estimating The Fair Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)
May 25A Look At The Intrinsic Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)
Feb 18Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Increasing Its Dividend To ₹25.00
Jan 27Here's Why Torrent Pharmaceuticals (NSE:TORNTPHARM) Can Manage Its Debt Responsibly
Jan 04Here's Why I Think Torrent Pharmaceuticals (NSE:TORNTPHARM) Is An Interesting Stock
Dec 14A Look At The Fair Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)
Nov 07Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Sep 30Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Deserve A Spot On Your Watchlist?
Sep 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jul 02I Ran A Stock Scan For Earnings Growth And Torrent Pharmaceuticals (NSE:TORNTPHARM) Passed With Ease
Jun 01Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Shares Could Be 30% Above Their Intrinsic Value Estimate
May 14Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?
Mar 23Rendement voor aandeelhouders
| TORNTPHARM | IN Pharmaceuticals | IN Markt | |
|---|---|---|---|
| 7D | 2.1% | 0.5% | 0.5% |
| 1Y | 51.5% | 42.5% | 27.5% |
Rendement versus industrie: TORNTPHARM overtrof de Indian Pharmaceuticals industrie, die het afgelopen jaar een rendement 42.5 % opleverde.
Rendement versus markt: TORNTPHARM overtrof de Indian markt, die het afgelopen jaar een rendement opleverde van 27.5 %.
Prijsvolatiliteit
| TORNTPHARM volatility | |
|---|---|
| TORNTPHARM Average Weekly Movement | 3.5% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.0% |
Stabiele aandelenkoers: TORNTPHARM heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van TORNTPHARM is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1959 | 15,718 | Samir Mehta | www.torrentpharma.com |
Torrent Pharmaceuticals Limited houdt zich bezig met onderzoek, ontwikkeling, productie en marketing van generieke farmaceutische formuleringen in India, de Verenigde Staten, Brazilië en Duitsland. Het bedrijf biedt producten in verschillende therapeutische gebieden, waaronder cardiovasculaire, centrale zenuwstelsel, gastro-intestinale en vrouwen gezondheidszorg; en dermatologie, diabetologie, pijnbestrijding, gynaecologie, oncologie en anti-infectie, evenals vitaminen, mineralen en voedingsstoffen. Het bedrijf levert ook contractproductiediensten.
Torrent Pharmaceuticals Limited Samenvatting
| TORNTPHARM fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | ₹1.07t |
| Inkomsten(TTM) | ₹18.02b |
| Inkomsten(TTM) | ₹112.24b |
59.5x
Koers/Winstverhouding9.6x
P/S-verhoudingIs TORNTPHARM overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| TORNTPHARM resultatenrekening (TTM) | |
|---|---|
| Inkomsten | ₹112.24b |
| Kosten van inkomsten | ₹27.48b |
| Brutowinst | ₹84.76b |
| Overige uitgaven | ₹66.73b |
| Inkomsten | ₹18.02b |
Laatst gerapporteerde inkomsten
Sep 30, 2024
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 53.25 |
| Brutomarge | 75.51% |
| Nettowinstmarge | 16.06% |
| Schuld/Eigen Vermogen Verhouding | 40.6% |
Hoe presteerde TORNTPHARM op de lange termijn?
Bekijk historische prestaties en vergelijking